FDA Approves Viral Immunotherapy for Advanced Melanoma Resistant to Anti-PD-1

The FDA has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a novel oncolytic viral immunotherapy, for adult patients with advanced unresectable cutaneous melanoma. The treatment is indicated in combination with nivolumab for patients whose disease has progressed despite prior anti-PD-1 checkpoint inhibitor therapy. This approval represents a significant therapeutic advancement for patients with treatment-resistant melanoma, offering a new combination strategy that engages the immune system through a distinct mechanism. Tudriqev works by infecting cancer cells with a modified herpes simplex virus, triggering immune activation alongside nivolumab's checkpoint inhibition, providing hope for patients who have exhausted conventional immunotherapy options.